Wrap Text
Transactions by persons discharging managerial responsibilities and persons closely associated with them
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(“Mediclinic”, the “Company” or the “Group”)
18 June 2018
NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL
RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
Awards granted under the Company's Short-Term Incentive Scheme
and Long-Term Incentive Plan
On 15 June 2018, awards over ordinary shares in Mediclinic (the “Shares”) were granted to the
following Directors and other persons discharging managerial responsibilities ("PDMRs") under the
Company’s Short-Term Incentive Scheme (the “STI”) and Long-Term Incentive Plan (the “LTIP”),
approved by shareholders in July 2017:
Name Director/ PDMR Number of Number of
Shares awarded Shares awarded
under the STI under the LTIP
Dr Ronnie van der Merwe Director n/a 200,128
Jurgens Myburgh Director 27,236 110,646
Danie Meintjes Director 45,811 209,998
David Hadley PDMR n/a 26,422
Gert Hattingh PDMR n/a 43,956
Magnus Oetiker PDMR n/a 59,701
Koert Pretorius PDMR n/a 48,121
Dr Dirk le Roux PDMR n/a 34,586
Dr Ole Wiesinger PDMR n/a 32,409
The awards made under the STI and LTIP were granted for nil consideration and are based on the
average of the middle-market quotations of a Share during a period of five dealing days ending with the
dealing day before the day of grant, which equates to £5.58 per Share.
The vesting of awards under the STI is subject to employment conditions only; no further performance
conditions apply. Awards granted under the LTIP are structured as conditional awards, with vesting
being subject to the satisfaction of performance conditions over a three-year period. Executive Directors
of Mediclinic will be required to hold vested awards for a further two years (i.e. until the fifth anniversary
of grant).
The notifications below are made in accordance with Articles 19.1 and 19.3 of the Market Abuse
Regulation.
1. Details of PDMR / person closely associated with them (“PCA”)
a) Name Dr Carel Aron van der Merwe
2. Reason for the notification
a) Position / status Chief Executive Officer of the Company
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long Term Incentive Plan
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 200,128
d) Aggregated
information
Aggregated volume 200,128
Price £nil
e) Date of the 15 June 2018
transaction
f) Place of the Outside a trading venue
transaction
1. Details of PDMR / person closely associated with them (“PCA”)
a) Name Petrus Jurgens Myburgh
2. Reason for the notification
a) Position / status Chief Financial Officer of the Company
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Short Term Incentive Scheme
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 27,236
d) Aggregated
information
Aggregated volume 27,236
Price £nil
e) Date of the 15 June 2018
transaction
f) Place of the Outside a trading venue
transaction
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long Term Incentive Plan
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 110,646
d) Aggregated
information
Aggregated volume 110,646
Price £nil
e) Date of the 15 June 2018
transaction
f) Place of the Outside a trading venue
transaction
1. Details of PDMR / person closely associated with them (“PCA”)
a) Name Daniël Petrus Meintjes
2. Reason for the notification
a) Position / status Executive Director of the Company
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Short Term Incentive Scheme
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 45,811
d) Aggregated
information
Aggregated volume 45,811
Price £nil
e) Date of the 15 June 2018
transaction
f) Place of the Outside a trading venue
transaction
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long Term Incentive Plan
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 209,998
d) Aggregated
information
Aggregated volume 209,998
Price £nil
e) Date of the 15 June 2018
transaction
f) Place of the Outside a trading venue
transaction
1. Details of PDMR / person closely associated with them (“PCA”)
a) Name David John Hadley
2. Reason for the notification
a) Position / status Chief Executive Officer – Mediclinic Middle East
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long Term Incentive Plan
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 26,422
d) Aggregated
information
Aggregated volume 26,422
Price £nil
e) Date of the 15 June 2018
transaction
f) Place of the Outside a trading venue
transaction
1. Details of PDMR / person closely associated with them (“PCA”)
a) Name Gert Cornelis Hattingh
2. Reason for the notification
a) Position / status Chief Corporate Services Officer of the Mediclinic Group
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long Term Incentive Plan
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 43,956
d) Aggregated
information
Aggregated volume 43,956
Price £nil
e) Date of the 15 June 2018
transaction
f) Place of the Outside a trading venue
transaction
1. Details of PDMR / person closely associated with them (“PCA”)
a) Name Magnus Ulrich Oetiker
2. Reason for the notification
a) Position / status Chief Human Resources Officer of the Mediclinic Group
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long Term Incentive Plan
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 59,701
d) Aggregated
information
Aggregated volume 59,701
Price £nil
e) Date of the 15 June 2018
transaction
f) Place of the Outside a trading venue
transaction
1. Details of PDMR / person closely associated with them (“PCA”)
a) Name Koert Hendrik Stefanus Pretorius
2. Reason for the notification
a) Position / status Chief Executive Officer – Mediclinic Southern Africa
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long Term Incentive Plan
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 48,121
d) Aggregated
information
Aggregated volume 48,121
Price £nil
e) Date of the 15 June 2018
transaction
f) Place of the Outside a trading venue
transaction
1. Details of PDMR / person closely associated with them (“PCA”)
a) Name Dr Dirk Cornelius le Roux
2. Reason for the notification
a) Position / status Chief Information Officer of the Mediclinic Group
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long Term Incentive Plan
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 34,586
d) Aggregated
information
Aggregated volume 34,586
Price £nil
e) Date of the 15 June 2018
transaction
f) Place of the Outside a trading venue
transaction
1. Details of PDMR / person closely associated with them (“PCA”)
a) Name Dr Thorsten Ole Wiesinger
2. Reason for the notification
a) Position / status Chief Executive Officer – Hirslanden
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long Term Incentive Plan
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 32,409
d) Aggregated
information
Aggregated volume 32,409
Price £nil
e) Date of the 15 June 2018
transaction
f) Place of the Outside a trading venue
transaction
About Mediclinic International plc
Mediclinic is an international private healthcare services group with operating divisions in Switzerland,
Southern Africa (South Africa and Namibia) and the United Arab Emirates. Its core purpose is to
enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary
healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, an LSE-listed
and UK-based private healthcare group.
Mediclinic comprises 75 hospitals and 28 clinics. Hirslanden operates 17 private acute care facilities
and 4 clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operates
49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 100
inpatient beds in total; and Mediclinic Middle East operates 6 hospitals and 22 clinics with more than
700 inpatient beds in the United Arab Emirates.
Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary
listings on the JSE in South Africa and the NSX in Namibia.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Jayne Meacham / Caroline Emmet
+44 (0)20 7954 9569
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Brett Pollard/Debbie Scott – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
Date: 18/06/2018 12:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
